These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 1961038)

  • 1. Susceptibility of adult acute lymphoblastic leukemia blasts to lysis by lymphokine-activated killer cells.
    Archimbaud E; Thomas X; Campos L; Magaud JP; Fiere D; Doré JF
    Leukemia; 1991 Nov; 5(11):967-71. PubMed ID: 1961038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility of acute myelogenous leukemia blasts to lysis by lymphokine-activated killer (LAK) cells and its clinical relevance.
    Archimbaud E; Thomas X; Campos L; Fiere D; Doré JF
    Leuk Res; 1992; 16(6-7):673-80. PubMed ID: 1378919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival.
    Lauria F; Raspadori D; Rondelli D; Ventura MA; Foà R
    Leukemia; 1994 May; 8(5):724-8. PubMed ID: 8182932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
    Teichmann JV; Ludwig WD; Thiel E
    Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion molecules.
    Arienti F; Gambacorti-Passerini C; Borin L; Rivoltini L; Orazi A; Pogliani EM; Corneo G; Parmiani G
    Ann Oncol; 1992 Feb; 3(2):155-62. PubMed ID: 1606087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
    LeFor AT; Eisenthal A; Rosenberg SA
    J Immunol; 1988 Jun; 140(11):4062-9. PubMed ID: 3259603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of human interleukin 3 on the susceptibility of fresh leukemia cells to interleukin-2-induced lymphokine activated killing activity.
    Cesano A; Lista P; Bellone G; Geuna M; Brizzi MF; Rossi PR; Pegoraro L; Oberholtzer E; Matera L
    Leukemia; 1992 Jun; 6(6):567-73. PubMed ID: 1376379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of leukemic cell sensitivity to lymphokine-activated killer cytolysis: role of intercellular adhesion molecule-1.
    Triozzi PL; Eicher DM; Smoot J; Rinehart JJ
    Exp Hematol; 1992 Oct; 20(9):1072-6. PubMed ID: 1361453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GM-CSF enhances IL-2-activated natural killer cell lysis of clonogenic AML cells by upregulating target cell expression of ICAM-1.
    Bendall LJ; Kortlepel K; Gottlieb DJ
    Leukemia; 1995 Apr; 9(4):677-84. PubMed ID: 7723403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of LAK cells in vitro in patients with acute leukemia.
    Parrado A; Rodriguez-Fernandez JM; Casares S; Noguerol P; Plaza E; Parody R; Espigado I; de Blas JM; Garcia-Solis D
    Leukemia; 1993 Sep; 7(9):1344-8. PubMed ID: 8371585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity.
    Fierro MT; Liao XS; Lusso P; Bonferroni M; Matera L; Cesano A; Lista P; Arione R; Forni G; Foa R
    Leukemia; 1988 Jan; 2(1):50-4. PubMed ID: 3257539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells.
    Lanza LA; Wilson DJ; Ikejiri B; Roth JA; Grimm EA
    J Immunol; 1986 Oct; 137(8):2716-20. PubMed ID: 3489774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.
    Rosenstein M; Yron I; Kaufmann Y; Rosenberg SA
    Cancer Res; 1984 May; 44(5):1946-53. PubMed ID: 6608989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease.
    Foa R; Fierro MT; Cesano A; Guarini A; Bonferroni M; Raspadori D; Miniero R; Lauria F; Gavosto F
    Blood; 1991 Aug; 78(4):1041-6. PubMed ID: 1868239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of adhesion molecules on acute leukemic blast cells and sensitivity to normal LAK activity.
    Raspadori D; Lauria F; Ventura MA; Rondelli D; Tura S
    Ann Hematol; 1993 Nov; 67(5):213-6. PubMed ID: 7694662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro resistance of the brown Norway rat acute myelocytic leukemia (BNML) to lymphokine-activated killer activity.
    Gaiser JF; Kloosterman TC; Martens AC; Hagenbeek A
    Leukemia; 1993 May; 7(5):736-41. PubMed ID: 8483327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of interleukin-2-stimulated lymphocytes and bispecific antibodies that efficiently lyse leukemic cells does not affect bone marrow CD34-positive stem cell function in vitro.
    Kaneko T; Fukuda J; Teramura M; Fusauchi Y; Kakui Y; Okumura K; Mizoguchi H; Oshimi K
    Bone Marrow Transplant; 1994 Aug; 14(2):213-7. PubMed ID: 7527685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of gamma interferon on the expression of class I MHC antigens on fresh leukemic cells and their susceptibility to lysis by lymphokine activated killer cells.
    Haridas V; Sarin A; Anandhi R; Kochupillai V; Saxena RK
    Indian J Cancer; 1994 Jun; 31(2):96-102. PubMed ID: 7927456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GM-CSF-mediated proliferation induction improves the susceptibility of leukemia cells to lymphokine-activated killer cells.
    Teichmann JV; Ludwig WD; Thiel E
    Int J Hematol; 1992 Jun; 55(3):255-64. PubMed ID: 1498316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.